Compare ROIV & ZION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | ZION |
|---|---|---|
| Founded | 2014 | 1873 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 9.4B |
| IPO Year | 2021 | N/A |
| Metric | ROIV | ZION |
|---|---|---|
| Price | $28.05 | $53.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 20 |
| Target Price | $27.56 | ★ $63.40 |
| AVG Volume (30 Days) | ★ 4.8M | 1.7M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $8.39 |
| Revenue Next Year | $385.85 | $4.65 |
| P/E Ratio | ★ N/A | $10.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $39.32 |
| 52 Week High | $30.33 | $66.18 |
| Indicator | ROIV | ZION |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 30.28 |
| Support Level | $26.94 | $46.34 |
| Resistance Level | N/A | $53.90 |
| Average True Range (ATR) | 1.01 | 1.70 |
| MACD | -0.21 | -0.61 |
| Stochastic Oscillator | 32.70 | 1.60 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.